"Eli Lilly Debuts Online Platform for Easier Access to Weight Loss Treatments"

Eli Lilly has launched LillyDirect, a website that connects patients with telehealth providers to prescribe and deliver their new FDA-approved weight loss drug, Zepbound, directly to patients' homes. This service aims to simplify access to their GLP-1 agonist class medication, which is effective but expensive and often not covered by insurance. Critics raise concerns about potential conflicts of interest and the implications for patient care continuity. Despite these concerns, Lilly assures that supply issues are not anticipated for Zepbound, unlike similar drugs in the market.